NASDAQ:ZIOP - ZIOPHARM Oncology News Headlines

$5.22
0.00 (0.00 %)
(As of 06/17/2019 03:00 AM ET)
Today's Range
$5.19
Now: $5.22
$5.52
50-Day Range
$4.07
MA: $4.42
$5.45
52-Week Range
$1.56
Now: $5.22
$5.52
Volume3.48 million shs
Average Volume1.48 million shs
Market Capitalization$847.15 million
P/E RatioN/A
Dividend YieldN/A
Beta2.52

Headlines

ZIOPHARM Oncology (NASDAQ ZIOP) News Headlines

Source:
DateHeadline
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) Receives Average Recommendation of "Buy" from AnalystsZIOPHARM Oncology Inc. (NASDAQ:ZIOP) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 16 at 4:36 AM
Ziopharm up 3% on FDA sign-off on study involving Sleeping Beauty platformZiopharm up 3% on FDA sign-off on study involving Sleeping Beauty platform
seekingalpha.com - June 11 at 4:46 PM
Ziopharm Trumpets Cancer TreatmentZiopharm Trumpets Cancer Treatment
www.baystreet.ca - June 11 at 11:18 AM
Ziopharm Oncology Announces FDA Clearance of IND for Sleeping Beauty TCR-T Cell Therapy Trial at NCIZiopharm Oncology Announces FDA Clearance of IND for Sleeping Beauty TCR-T Cell Therapy Trial at NCI
finance.yahoo.com - June 11 at 11:18 AM
ZIOPHARM Oncology (ZIOP) Presents At 2019 Jefferies Global Healthcare Conference - SlideshowZIOPHARM Oncology (ZIOP) Presents At 2019 Jefferies Global Healthcare Conference - Slideshow
seekingalpha.com - June 7 at 7:05 PM
Ziopharm in-licenses IP from NCI for cancer cell therapies; sharse up 2% after hoursZiopharm in-licenses IP from NCI for cancer cell therapies; sharse up 2% after hours
seekingalpha.com - June 6 at 4:43 PM
Ziopharm Oncology Provides Positive Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 ASCO Annual MeetingZiopharm Oncology Provides Positive Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 ASCO Annual Meeting
www.nasdaq.com - June 2 at 9:57 AM
Ziopharm Oncology Provides Positive Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 ASCO Annual MeetingZiopharm Oncology Provides Positive Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 ASCO Annual Meeting
finance.yahoo.com - June 2 at 9:57 AM
The Week Ahead In Biotech: ASCO Presentations Pick Up The PaceThe Week Ahead In Biotech: ASCO Presentations Pick Up The Pace
feeds.benzinga.com - June 1 at 1:33 PM
Ziopharm in-licenses IP from NCI for cancer cell therapies; shares up 2% after hoursZiopharm in-licenses IP from NCI for cancer cell therapies; shares up 2% after hours
seekingalpha.com - May 29 at 10:33 AM
Ziopharm Oncology Announces Exclusive License with National Cancer Institute to Identify and Use T-Ziopharm Oncology Announces Exclusive License with National Cancer Institute to Identify and Use T-
www.nasdaq.com - May 28 at 4:31 PM
Ziopharm Oncology Announces Exclusive License with National Cancer Institute to Identify and Use T-Cell Receptors Targeting Neoantigens for Cancer with Sleeping Beauty PlatformZiopharm Oncology Announces Exclusive License with National Cancer Institute to Identify and Use T-Cell Receptors Targeting Neoantigens for Cancer with Sleeping Beauty Platform
finance.yahoo.com - May 28 at 4:31 PM
ZIOPHARM Oncology Inc. (ZIOP) Expected to Post Earnings of -$0.08 Per ShareZIOPHARM Oncology Inc. (ZIOP) Expected to Post Earnings of -$0.08 Per Share
www.americanbankingnews.com - May 26 at 12:10 AM
Ziopharm Oncology Presentation at the Jefferies 2019 Global Healthcare Conference to be WebcastZiopharm Oncology Presentation at the Jefferies 2019 Global Healthcare Conference to be Webcast
finance.yahoo.com - May 23 at 4:46 PM
Edited Transcript of ZIOP earnings conference call or presentation 8-May-19 8:30pm GMTEdited Transcript of ZIOP earnings conference call or presentation 8-May-19 8:30pm GMT
finance.yahoo.com - May 9 at 11:17 AM
Ziopharm Oncology to Host Conference Call to Discuss First Quarter 2019 Financial Results on May 8, 2019Ziopharm Oncology to Host Conference Call to Discuss First Quarter 2019 Financial Results on May 8, 2019
finance.yahoo.com - May 2 at 11:12 AM
What Kind Of Shareholder Appears On The ZIOPHARM Oncology, Inc.s (NASDAQ:ZIOP) Shareholder Register?What Kind Of Shareholder Appears On The ZIOPHARM Oncology, Inc.'s (NASDAQ:ZIOP) Shareholder Register?
finance.yahoo.com - April 16 at 3:56 PM
What Kind Of Shareholder Appears On The ZIOPHARM Oncology, Inc.'s (NASDAQ:ZIOP) Shareholder Register?What Kind Of Shareholder Appears On The ZIOPHARM Oncology, Inc.'s (NASDAQ:ZIOP) Shareholder Register?
finance.yahoo.com - April 16 at 3:56 PM
Phio Pharmaceuticals Appoints Dr. John Barrett as Chief Development OfficerPhio Pharmaceuticals Appoints Dr. John Barrett as Chief Development Officer
finance.yahoo.com - April 10 at 10:23 AM
Ziopharmas Lead Asset Snags Fast Track Designation For Cancer TreatmentZiopharma's Lead Asset Snags Fast Track Designation For Cancer Treatment
finance.yahoo.com - April 1 at 4:07 PM
Ziopharms Ad-RTS-hIL-12 plus Veledimex Fast Trackd for rGBM; shares up 8% premarketZiopharm's Ad-RTS-hIL-12 plus Veledimex Fast Track'd for rGBM; shares up 8% premarket
seekingalpha.com - April 1 at 12:47 PM
Ziopharm Oncology Announces FDA Fast Track Designation for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Recurrent GlioblastomaZiopharm Oncology Announces FDA Fast Track Designation for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Recurrent Glioblastoma
finance.yahoo.com - April 1 at 12:46 PM
ZIOPHARM Oncology Inc Estimate MomentumZIOPHARM Oncology Inc Estimate Momentum
www.nasdaq.com - March 20 at 9:30 PM
Edited Transcript of ZIOP earnings conference call or presentation 5-Mar-19 9:30pm GMTEdited Transcript of ZIOP earnings conference call or presentation 5-Mar-19 9:30pm GMT
finance.yahoo.com - March 6 at 11:15 AM
Ziopharm Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate UpdateZiopharm Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - March 5 at 4:26 PM
ZIOPHARM Oncology Inc (ZIOP)ZIOPHARM Oncology Inc (ZIOP)
www.zacks.com - March 1 at 11:50 AM
Ziopharm Oncology to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on March 5Ziopharm Oncology to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on March 5
finance.yahoo.com - February 25 at 10:55 AM
Ziopharm Oncology CEO to Present at the CAR-TCR Summit EuropeZiopharm Oncology CEO to Present at the CAR-TCR Summit Europe
finance.yahoo.com - February 21 at 12:43 PM
Spring Bank Pharmaceuticals Appoints Atif Abbas, M.D., as Vice President, Head of Oncology & Immunology Clinical DevelopmentSpring Bank Pharmaceuticals Appoints Atif Abbas, M.D., as Vice President, Head of Oncology & Immunology Clinical Development
www.benzinga.com - February 20 at 11:57 AM
Constellation Pharmaceuticals Announces Appointment to Board of DirectorsConstellation Pharmaceuticals Announces Appointment to Board of Directors
www.marketwatch.com - February 20 at 11:57 AM
Is ZIOPHARM Oncology, Inc.’s (NASDAQ:ZIOP) CEO Paid At A Competitive Rate?Is ZIOPHARM Oncology, Inc.’s (NASDAQ:ZIOP) CEO Paid At A Competitive Rate?
finance.yahoo.com - February 13 at 4:28 PM
Ziopharm completes enrollment in early-stage study of Controlled IL-12 in brain cancerZiopharm completes enrollment in early-stage study of Controlled IL-12 in brain cancer
seekingalpha.com - February 12 at 4:16 PM
Ziopharm Oncology Completes Enrollment of Controlled IL-12 Monotherapy Expansion Substudy in Phase 1 Brain Cancer Trial - GlobeNewswireZiopharm Oncology Completes Enrollment of Controlled IL-12 Monotherapy Expansion Substudy in Phase 1 Brain Cancer Trial - GlobeNewswire
globenewswire.com - February 11 at 4:22 PM
Ziopharm Oncology Completes Enrollment of Controlled IL-12 Monotherapy Expansion Substudy in Phase 1 Brain Cancer TrialZiopharm Oncology Completes Enrollment of Controlled IL-12 Monotherapy Expansion Substudy in Phase 1 Brain Cancer Trial
finance.yahoo.com - February 11 at 8:26 AM
ZIOPHARM Oncology (ZIOP) Presents At 37th Annual J.P. Morgan Healthcare Conference - SlideshowZIOPHARM Oncology (ZIOP) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
seekingalpha.com - January 11 at 4:44 PM
Ziopharm Oncology Posts Letter to StockholdersZiopharm Oncology Posts Letter to Stockholders
finance.yahoo.com - January 7 at 4:38 PM
Ziopharm Oncology Responds to Recent Stock Decline and Clarifies Exclusivity Rights for Clinical AssetsZiopharm Oncology Responds to Recent Stock Decline and Clarifies Exclusivity Rights for Clinical Assets
finance.yahoo.com - December 27 at 4:21 PM
Do Hedge Funds Love ZIOPHARM Oncology Inc. (ZIOP)?Do Hedge Funds Love ZIOPHARM Oncology Inc. (ZIOP)?
finance.yahoo.com - December 24 at 10:09 AM
Ziopharm Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference - GlobeNewswireZiopharm Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
globenewswire.com - December 21 at 4:19 PM
Ziopharm Oncology to Present at the 37th Annual J.P. Morgan Healthcare ConferenceZiopharm Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 21 at 9:48 AM
BRIEF-Ziopharm Oncology And TriArm Therapeutics Establish Joint Venture To Develop And Commercialize Sleeping Beauty CAR T In China, Taiwan & KoreaBRIEF-Ziopharm Oncology And TriArm Therapeutics Establish Joint Venture To Develop And Commercialize Sleeping Beauty CAR T In China, Taiwan & Korea
www.msn.com - December 19 at 10:02 AM
Ziopharm up 7% premarket on JV in AsiaZiopharm up 7% premarket on JV in Asia
seekingalpha.com - December 19 at 10:02 AM
Ziopharm Oncology and TriArm Therapeutics Establish Joint Venture to Develop and Commercialize Sleeping Beauty CAR T in China, Taiwan and KoreaZiopharm Oncology and TriArm Therapeutics Establish Joint Venture to Develop and Commercialize Sleeping Beauty CAR T in China, Taiwan and Korea
finance.yahoo.com - December 19 at 10:02 AM
The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive PatchThe Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch
finance.yahoo.com - December 14 at 4:07 PM
Ziopharm Oncology Promotes Dr. David Mauney to PresidentZiopharm Oncology Promotes Dr. David Mauney to President
finance.yahoo.com - December 13 at 4:30 PM
Are Options Traders Betting on a Big Move in ZIOPHARM Oncology (ZIOP) Stock?Are Options Traders Betting on a Big Move in ZIOPHARM Oncology (ZIOP) Stock?
finance.yahoo.com - November 29 at 10:23 AM
Ziopharm Oncology (ZIOP) Provides Controlled IL-12 Update with Positive Data from Phase 1 Trial Presented at SNOZiopharm Oncology (ZIOP) Provides Controlled IL-12 Update with Positive Data from Phase 1 Trial Presented at SNO
www.streetinsider.com - November 17 at 9:39 AM
Ziopharm slips 1% after hours following release of early-stage data on gene therapy Controlled IL-12Ziopharm slips 1% after hours following release of early-stage data on gene therapy Controlled IL-12
seekingalpha.com - November 17 at 9:39 AM
Ziopharm Oncology Provides Controlled IL-12 Update with Positive Data from Phase 1 Trial PresentedZiopharm Oncology Provides Controlled IL-12 Update with Positive Data from Phase 1 Trial Presented
www.nasdaq.com - November 16 at 4:16 PM
BRIEF-ZIOPHARM Oncology Provides Update On Its Controlled IL-12 PlatformBRIEF-ZIOPHARM Oncology Provides Update On Its Controlled IL-12 Platform
www.msn.com - November 16 at 4:16 PM
This page was last updated on 6/17/2019 by MarketBeat.com Staff

Featured Article: Percentage Gainers

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel